NF2 and neoplasm: Given the fact that brigatinib caused tumor shrinkage in both NF2 associated schwannoma and meningioma, a clinical trial was initiated to assess the therapeutic effectiveness of brigatinib in NF2-associated tumors (ClinicalTrials.gov: NCT04374305).